全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Concurrent Dual Contrast for Cellular Magnetic Resonance Imaging Using Gadolinium Oxide and Iron Oxide Nanoparticles

DOI: 10.1155/2012/230942

Full-Text   Cite this paper   Add to My Lib

Abstract:

Rationale and Objectives. Concurrent visualization of differential targets in cellular and molecular imaging is valuable for resolving processes spatially and temporally, as in monitoring different cell subtypes. The purpose of this study was to demonstrate concurrent, dual (positive and negative) contrast visualization on magnetic resonance imaging (MRI) of two colocalized cell populations labeled with Gadolinium “Gd” oxide and iron “Fe” oxide nanoparticles. Materials and Methods. Human aortic endothelial cells (EC) and smooth muscle cells (SMC) were labeled with various concentrations of Gd oxide and Fe oxide, respectively. MRI on single- or mixed-cell samples was performed at 7 tesla. Proper cell phenotype expressions, cell uptake of contrast agents, and the effect of labeling on cell viability and proliferation were also determined. Results. Both contrast agents were efficiently taken up by cells, with viability and proliferation largely unaffected. On MRI, the positive contrast associated with Gd oxide-labeled EC and negative contrast associated with Fe oxide-labeled SMC discriminated the presence of each cell type, whether it existed alone or colocalized in a mixed-cell sample. Conclusion. It is feasible to use Gd oxide and Fe oxide for dual contrast and concurrent discrimination of two colocalized cell populations on MRI at 7 tesla. 1. Introduction Contrast agents play a critical role in cellular and molecular magnetic resonance imaging (MRI), as they enable sensitive and clear visualization of cellular and physiological processes. The different contrast agents available for labeling cells share in common their ability to enhance signal contrast and have facilitated cell-tracking studies in stem cell transplantation, neurodegenerative disorders and stroke, atherosclerosis, and cancer research [1–4]. Superparamagnetic iron oxide nanoparticles are by far the most common, owing to their strong negative -weighted contrast, and have been widely used for tracking different cell types in various organs, including lymphocytes, progenitor cells, and embryonic cells [5–9]. Less common are paramagnetic gadolinium (Gd-) based agents, which exploit positive -weighted contrast changes. These have been used in their chelated form for tracking stem cells in animal models of hemorrhagic transformation [10] and angiogenesis [11] and, more recently, in a nanoparticle formulation for improved cell uptake and retention [12]. However, in virtually all of the reported cellular MRI applications, only one cell population could be labeled and tracked. The ability to track

References

[1]  D. L. Kraitchman, A. W. Heldman, E. Atalar et al., “In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction,” Circulation, vol. 107, no. 18, pp. 2290–2293, 2003.
[2]  L. M. Bernas, P. J. Foster, and B. K. Rutt, “Imaging iron-loaded mouse glioma tumors with bSSFP at 3 T,” Magnetic Resonance in Medicine, vol. 64, no. 1, pp. 23–31, 2010.
[3]  J. Shen, X. M. Zhong, X. H. Duan et al., “Magnetic resonance imaging of mesenchymal stem cells labeled with dual (MR and Fluorescence) agents in rat spinal cord injury,” Academic Radiology, vol. 16, no. 9, pp. 1142–1154, 2009.
[4]  K. J. Saldanha, R. P. Doan, K. M. Ainslie, T. A. Desai, and S. Majumdar, “Micrometer-sized iron oxide particle labeling of mesenchymal stem cells for magnetic resonance imaging-based monitoring of cartilage tissue engineering,” Magnetic Resonance Imaging, vol. 29, no. 1, pp. 40–49, 2011.
[5]  T. C. Yeh, W. Zhang, S. T. Ildstad, and C. Ho, “Intracellular labeling of T-cells with superparamagnetic contrast agents,” Magnetic Resonance in Medicine, vol. 30, no. 5, pp. 617–625, 1993.
[6]  M. Hoehn, E. Küstermann, J. Blunk et al., “Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16267–16272, 2002.
[7]  I. J. M. de Vries, W. J. Lesterhuis, J. O. Barentsz et al., “Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy,” Nature Biotechnology, vol. 23, no. 11, pp. 1407–1413, 2005.
[8]  S. Li Calzi, D. L. Kent, K. H. Chang et al., “Labeling of stem cells with monocrystalline iron oxide for tracking and localization by magnetic resonance imaging,” Microvascular Research, vol. 78, no. 1, pp. 132–139, 2009.
[9]  M. Lewin, N. Carlesso, C. H. Tung et al., “Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells,” Nature Biotechnology, vol. 18, no. 4, pp. 410–414, 2000.
[10]  F. L. Giesel, M. Stroick, M. Griebe et al., “Gadofluorine M uptake in stem cells as a new magnetic resonance imaging tracking method: an in vitro and in vivo study,” Investigative Radiology, vol. 41, no. 12, pp. 868–873, 2006.
[11]  S. G. Crich, L. Biancone, V. Cantaluppi et al., “Improved route for the visualization of stem cells labeled with a Gd-/Eu-chelate as dual (MRI and Fluorescence) agent,” Magnetic Resonance in Medicine, vol. 51, no. 5, pp. 938–944, 2004.
[12]  L. Faucher, A. A. Guay-Begin, J. Lagueux, M. F. Cote, E. Petitclerc, and M. A. Fortin, “Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI,” Contrast Media & Molecular Imaging, vol. 6, pp. 209–218, 2011.
[13]  A. A. Gilad, P. Walczak, M. T. McMahon et al., “MR tracking of transplanted cells with “positive contrast” using manganese oxide nanoparticles,” Magnetic Resonance in Medicine, vol. 60, no. 1, pp. 1–7, 2008.
[14]  A. A. Gilad, H. W. M. Van Laarhoven, M. T. Mcmahon et al., “Feasibility of concurrent dual contrast enhancement using CEST contrast agents and superparamagnetic iron oxide particles,” Magnetic Resonance in Medicine, vol. 61, no. 4, pp. 970–974, 2009.
[15]  M. T. McMahon, A. A. Gilad, M. A. DeLiso, S. M. Cromer Berman, J. W. M. Bulte, and P. C. M. Van Zijl, “New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI,” Magnetic Resonance in Medicine, vol. 60, no. 4, pp. 803–812, 2008.
[16]  T. Tagami, W. D. Foltz, M. J. Ernsting et al., “MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome,” Biomaterials, vol. 32, no. 27, pp. 6570–6578, 2011.
[17]  C. S. Poon and R. M. Henkelman, “Practical T2 quantitation for clinical applications.,” Journal of Magnetic Resonance Imaging, vol. 2, no. 5, pp. 541–553, 1992.
[18]  Y. Tang, K. Shah, S. M. Messerli, E. Snyder, X. Breakefield, and R. Weissleder, “In vivo tracking of neural progenitor cell migration to glioblastomas,” Human Gene Therapy, vol. 14, no. 13, pp. 1247–1254, 2003.
[19]  K. M. Ward, A. H. Aletras, and R. S. Balaban, “A new class of contrast agents for MRI based on proton chemical exchange dependent Saturation transfer (CEST),” Journal of Magnetic Resonance, vol. 143, no. 1, pp. 79–87, 2000.
[20]  E. Terreno, D. D. Castelli, L. Milone et al., “First ex-vivo MRI co-localization of two LIPOCEST agents,” Contrast Media and Molecular Imaging, vol. 3, no. 1, pp. 38–43, 2008.
[21]  A. E. Merbach and E. Toth, The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging, John Wiley & Sons, Chichester, UK, 2001.
[22]  H. E. Daldrup-Link, M. Rudelius, R. A. J. Oostendorp et al., “Targeting of hematopoietic progenitor cells with MR contrast agents,” Radiology, vol. 228, no. 3, pp. 760–767, 2003.
[23]  J. K. Hsiao, M. F. Tai, H. H. Chu et al., “Magnetic nanoparticle labeling of mesenchymal stem cells without transfection agent: cellular behavior and capability of detection with clinical 1.5 T magnetic resonance at the single cell level,” Magnetic Resonance in Medicine, vol. 58, no. 4, pp. 717–724, 2007.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133